Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Feb 18;14(4):e038736.
doi: 10.1161/JAHA.124.038736. Epub 2025 Feb 14.

Anticoagulation in Atrial Fibrillation With Valvular Heart Disease

Ana Catarina Fonseca  1   2 , Claúdia Jorge  3
Affiliations
Editorial

Anticoagulation in Atrial Fibrillation With Valvular Heart Disease

Ana Catarina Fonseca et al. J Am Heart Assoc. .
No abstract available

Keywords: Editorials; anticoagulants; atrial fibrillation; blood coagulation; health services; heart valve diseases.

PubMed Disclaimer

Conflict of interest statement

Dr Fonseca reports receiving payment from participation in an Advisory Board for Bayer outside the scope of this article. Dr Jorge has no disclosures to report.

Figures

Figure 1
Figure 1. Current indications for treatment with direct oral anticoagulants or vitamin K antagonists in patients with AF and VHD.
DOACs indicates direct oral anticoagulants; EHRA, Evaluating Heart Valve, Rheumatic, or Artificial; VHD, valvular heart disease; and VKAs, vitamin K antagonists.
See this image and copyright information in PMC

Comment on

References

    1. Carnicelli AP, Hong H, Connolly SJ, Eikelboom J, Giugliano RP, Morrow DA, Patel MR, Wallentin L, Alexander JH, Cecilia Bahit M, et al. Direct Oral anticoagulants versus warfarin in patients with atrial fibrillation: patient‐level network meta‐analyses of randomized clinical trials with interaction testing by age and sex. Circulation. 2022;145:242–255. doi: 10.1161/CIRCULATIONAHA.121.056355 - DOI - PMC - PubMed
    1. Lip GYH, Jensen M, Melgaard L, Skjøth F, Nielsen PB, Larsen TB. Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating ‘valvular heart disease’ in a nationwide cohort study. Europace. 2019;21:33–40. doi: 10.1093/europace/euy151 - DOI - PubMed
    1. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206–1214. doi: 10.1056/NEJMoa1300615 - DOI - PubMed
    1. Wang TY, Svensson LG, Wen J, Vekstein A, Gerdisch M, Rao VU, Moront M, Johnston D, Lopes RD, Chavez A, et al. Apixaban or warfarin in patients with an on‐X mechanical aortic valve. NEJM Evid. 2023;2:EVIDoa2300067. doi: 10.1056/EVIDoa2300067 - DOI - PubMed
    1. Connolly SJ, Karthikeyan G, Ntsekhe M, Haileamlak A, El Sayed A, El Ghamrawy A, Damasceno A, Avezum A, Dans AML, Gitura B. Rivaroxaban in rheumatic heart disease‐associated atrial fibrillation. N Engl J Med. 2022;387:978–988. doi: 10.1056/NEJMoa2209051 - DOI - PubMed

LinkOut - more resources